论文部分内容阅读
目的:探讨华法林对于非瓣膜病性心房纤颤(房颤)患者抗凝治疗的安全性及疗效。方法:对符合本研究标准的60例老年房颤患者随机分为治疗组和对照组;治疗组30例,给予华法林3mg/日开始,监测国际标准化比值(INR),连续观察4周,目标INR2.0～3.0,后每月查1次INR,据INR结果调整华法林口服剂量。对照组30例给予阿司匹林300mg/日。结果:治疗组2例牙龈、皮肤出血,1例脑梗死。对照组1例出血,8例脑卒中,1例动脉栓塞,2组出血并发症无差异(P>0.05),血栓性并发症治疗组显著低于对照组(P<0.01)。结论:非瓣膜病性心房纤颤患者应用适量华法林抗凝治疗是安全有效的。
Objective: To investigate the safety and efficacy of warfarin in anticoagulant therapy in patients with nonvalvular atrial fibrillation (AF). Methods: A total of 60 elderly AF patients who met the criteria of this study were randomly divided into treatment group and control group. The treatment group (n = 30) received warfarin 3 mg / d for monitoring the international normalized ratio (INR) The target INR 2.0 ~ 3.0, after a monthly check INR, adjusted according to INR results warfarin oral dose. Control group 30 patients given aspirin 300mg / day. Results: The treatment group 2 cases of gums, skin bleeding, 1 case of cerebral infarction. There were no significant differences in bleeding complications between the two groups (P> 0.05). Thrombosis complications were significantly lower in the control group than in the control group (P <0.01). Conclusion: Appropriate warfarin anticoagulation is safe and effective in patients with nonvalvular atrial fibrillation.